✨
AI Summary
- Dr. Oren Gilad discusses precision oncology and synthetic lethality at Aprea Therapeutics.
- Developing next-generation therapies targeting unique cancer genetic vulnerabilities.
- Biomarker-driven drug development is key for improving safety and efficacy.
Guests on This Episode
OG
Oren Gilad
2 podcast appearances